First‑Line Antibiotic Selection for Community‑Acquired Lower Respiratory Tract Infection

Guideline Recommendations (European Respiratory Society)

• The European Respiratory Society recommends plain amoxicillin (an aminopenicillin) as the first‑choice oral agent for home‑managed community‑acquired LRTI in adults without risk factors for severe disease or atypical pathogens. 1
• Oral cephalosporins, including cefuroxime, are listed only as alternatives and not as first‑line agents in the European guideline hierarchy. 1

When Amoxicillin‑Clavulanate Is Preferred (Risk‑Based)

• Amoxicillin‑clavulanate is specifically recommended when any of the following are present:

• In patients with the above risk factors, the guideline advises choosing amoxicillin‑clavulanate over cefuroxime as the preferred oral β‑lactam agent. 1

Role of Cefuroxime (Alternative Agent)

• Cefuroxime axetil (500 mg twice daily) is positioned as an alternative oral β‑lactam for community‑acquired LRTI when amoxicillin‑clavulanate cannot be used (e.g., contraindication or patient preference for twice‑daily dosing). It is not recommended as the default first‑line option. 1

Treatment Duration and Follow‑Up

• The standard course of therapy for uncomplicated community‑acquired LRTI is 5–7 days. 1
• Patients should be reassessed if fever persists beyond 48 hours after initiating therapy. 1

Critical Pitfalls to Avoid (European Guidance)

• Do not use cefuroxime as automatic first‑line in patients with chronic lung disease or recent antibiotic exposure; amoxicillin‑clavulanate is the guideline‑endorsed choice for these scenarios. 1
• Avoid oral cephalosporins when β‑lactamase‑producing organisms are suspected, because amoxicillin‑clavulanate provides superior coverage of such pathogens. 1
• Persistent cough after completing the antibiotic course is common and does not necessarily indicate treatment failure. 1